There have been a number of developments globally in recent weeks on the AstraZeneca COVID-19 vaccine, including concerns related to vaccine-induced immune thrombocytopenia (VITT).

VITT (also known as vaccine-induced prothrombotic immune thrombocytopenia/VIPIT) is a rare adverse event characterized by serious blood clots, including cerebral venous sinus thrombosis, associated with thrombocytopenia. Numerous countries have reported cases of VITT following post-licensure use of the AstraZeneca vaccine. The exact mechanism by which the vaccine may trigger VITT is still under investigation.

Several federal and provincial public health organizations in Canada have developed statements on the AstraZeneca COVID-19 vaccine and VITT:

**Health Canada - Safety Information for Health Care Providers**


**Health Canada - Regulatory Statement**


**National Advisory Committee on Immunization Statement:**


**Council of Chief Medical Officers of Health Statement:**


**Clinical Guidance from Provincial Partners**

**Ontario Science Table**


FR: Coming Soon

**Government of Quebec**

EN: Coming soon